Population-based surveillance shows fidaxomicin reduces recurrence in community-associated CDI, implying better outpatient management.
Using population-based surveillance from 2020 to 2024, we examined recurrence through 180 days among adults with initial community-associated Clostridioides difficile infection (CDI). Fidaxomicin was associated with a 50% lower risk of recurrence compared with vancomycin. These findings are consistent with current guideline recommendations and are relevant to outpatient management of initial CDI.
No takes yet. Share an insight, caveat, or question.
Hawco et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: